Related Experiment Video

Updated: Sep 21, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?

Mahmoud Al Rifai1, L Kristin Newby2,3, Ajith P Nair1

  • 1Section of Cardiology, Department of Medicine, Baylor College of Medicine, 2002 Holcombe Blvd, Houston, TX, 77030, USA.

Current Atherosclerosis Reports
|June 2, 2022
PubMed
Abstract

Insights

Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) show significant cardiovascular benefits. These drugs are now recommended for preventing and treating heart failure (HF) in various patient groups.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Heart failure (HF) remains a leading cause of morbidity and mortality worldwide.
  • Existing treatments for HF have limitations in fully addressing the complex pathophysiology.
  • Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were initially developed for diabetes but exhibit cardioprotective properties.

Purpose of the Study:

  • To review the mechanisms of action of SGLT-2i.
  • To discuss the evidence supporting the protective effects of SGLT-2i in mitigating heart failure outcomes.
  • To highlight the role of SGLT-2i in current HF management guidelines.

Main Methods:

  • Systematic review of major randomized clinical trials (RCTs) involving SGLT-2i.
  • Analysis of data from trials including patients with and without heart failure.
  • Evaluation of guideline recommendations incorporating SGLT-2i for HF treatment.

Main Results:

  • RCTs confirm the cardiovascular safety and efficacy of SGLT-2i across diverse patient populations.
  • SGLT-2i demonstrated benefits in patients with heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).
  • Recent guidelines now include SGLT-2i as a key component of HF treatment strategies.

Conclusions:

  • SGLT-2i represent a novel therapeutic class for both the prevention and treatment of heart failure.
  • These agents effectively reduce cardiovascular morbidity and mortality in patients with HFrEF and HFpEF.
  • SGLT-2i are transforming the landscape of heart failure management.
Keywords:
Heart failure (HF)Heart failure with preserved ejection fraction (HFpEF)Heart failure with reduced ejection fraction (HFrEF)Sodium-glucose cotransporter-2 inhibitors (SGLT-2i)

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
528
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
42
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
751
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
506
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
447